Filip Jankú

26.6k total citations · 6 hit papers
430 papers, 14.9k citations indexed

About

Filip Jankú is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Filip Jankú has authored 430 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Oncology, 159 papers in Molecular Biology and 158 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Filip Jankú's work include Cancer Genomics and Diagnostics (118 papers), Lung Cancer Treatments and Mutations (77 papers) and Colorectal Cancer Treatments and Studies (68 papers). Filip Jankú is often cited by papers focused on Cancer Genomics and Diagnostics (118 papers), Lung Cancer Treatments and Mutations (77 papers) and Colorectal Cancer Treatments and Studies (68 papers). Filip Jankú collaborates with scholars based in United States, United Kingdom and Netherlands. Filip Jankú's co-authors include Razelle Kurzrock, David S. Hong, Funda Meric‐Bernstam, Aung Naing, Apostolia M. Tsimberidou, Jiří Polívka, Siqing Fu, Sarina A. Piha‐Paul, Gerald S. Falchook and Timothy A. Yap and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Filip Jankú

417 papers receiving 14.7k citations

Hit Papers

Targeting the PI3K pathway in cancer: are we m... 2011 2026 2016 2021 2018 2011 2013 2015 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting the PI3K pathway in cancer: are we making headway?
    2018 787 citations Filip Jankú, Funda Meric‐Bernstam et al. profile →
  2. Autophagy as a target for anticancer therapy
    2011 680 citations Filip Jankú, David S. Hong et al. profile →
  3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
    2013 644 citations Filip Jankú et al. profile →
  4. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
    2015 513 citations Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology profile →
  5. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Josep Tabernero, Filip Jankú et al. Journal of Clinical Oncology profile →
  6. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
    2023 84 citations Sarina A. Piha‐Paul, Filip Jankú et al. Clinical Cancer Research profile →

Peers

Filip Jankú
David S. Hong United States
Sandrine Faivre France
Bryan T. Hennessy Ireland
Antonio Russo Italy
Aung Naing United States
Nicola Normanno Italy
Stefan Sleijfer Netherlands
Frédérique Penault‐Llorca France
Kazuto Nishio Japan
Masakazu Toi Japan
David S. Hong United States
Filip Jankú
Citations per year, relative to Filip Jankú Filip Jankú (= 1×) peers David S. Hong

Countries citing papers authored by Filip Jankú

Since Specialization
Citations

This map shows the geographic impact of Filip Jankú's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Jankú with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Jankú more than expected).

Fields of papers citing papers by Filip Jankú

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Jankú. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Jankú. The network helps show where Filip Jankú may publish in the future.

Co-authorship network of co-authors of Filip Jankú

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Jankú. A scholar is included among the top collaborators of Filip Jankú based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Jankú. Filip Jankú is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Voss, Martin H., Cinta Hierro, Rebecca S. Heist, et al.. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research. 25(9). 2699–2707. 102 indexed citations
2.
Falchook, Gerald S., Razelle Kurzrock, Hesham M. Amin, et al.. (2019). First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1237–1246. 67 indexed citations
3.
Hess, Kenneth R., Filip Jankú, Nora Sánchez, et al.. (2019). Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research. 26(8). 1924–1931. 40 indexed citations
4.
Hong, David S., Patricia LoRusso, Omid Hamid, et al.. (2018). Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 25(8). 2403–2413. 42 indexed citations
5.
Kehl, Kenneth L., Siqing Fu, Goldy C. George, et al.. (2017). Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research. 23(15). 4155–4162. 4 indexed citations
6.
Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics. 15(10). 2475–2485. 73 indexed citations
7.
Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research. 76(13). 3690–3701. 149 indexed citations
8.
Kopetz, Scott, Jayesh Desai, Emily Chan, et al.. (2015). Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer. Journal of Clinical Oncology. 33(34). 4032–4038. 513 indexed citations breakdown →
9.
Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations
10.
Ganesan, Prasanth, Stacy L. Moulder, J. Jack Lee, et al.. (2014). Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics. 13(12). 3175–3184. 29 indexed citations
11.
Hyman, David M., Eli L. Diamond, Cecile Rose T. Vibat, et al.. (2014). Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery. 5(1). 64–71. 84 indexed citations
12.
Jardim, Denis L., Chad Tang, Débora De Melo Gagliato, et al.. (2014). Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research. 20(24). 6336–6345. 65 indexed citations
13.
Tsimberidou, Apostolia M., Sijin Wen, David S. Hong, et al.. (2014). Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. Clinical Cancer Research. 20(18). 4827–4836. 140 indexed citations
14.
Tang, Chad, Kenneth R. Hess, Denis L. Jardim, et al.. (2014). Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clinical Cancer Research. 20(23). 5956–5963. 11 indexed citations
15.
Ganesan, Prasanth, Filip Jankú, Aung Naing, et al.. (2013). Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Molecular Cancer Therapeutics. 12(12). 2857–2863. 38 indexed citations
16.
Tsimberidou, Apostolia M., Nancy G. Iskander, David S. Hong, et al.. (2012). Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research. 18(22). 6373–6383. 387 indexed citations
17.
Jankú, Filip, Donald A. Berry, Jing Gong, et al.. (2012). Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009. Clinical Cancer Research. 18(22). 6356–6363. 20 indexed citations
18.
Jankú, Filip, Jennifer J. Wheler, Aung Naing, et al.. (2012). PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research. 73(1). 276–284. 218 indexed citations
19.
Jankú, Filip, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, et al.. (2011). PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics. 10(3). 558–565. 289 indexed citations
20.
Garrido‐Laguna, Ignacio, Filip Jankú, Gerald S. Falchook, et al.. (2010). Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment. Clinical Cancer Research. 16(15). 4031–4037. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Hong Breakdown of academic impact, for papers by Sandrine Faivre Breakdown of academic impact, for papers by Bryan T. Hennessy Breakdown of academic impact, for papers by Antonio Russo Breakdown of academic impact, for papers by Aung Naing Breakdown of academic impact, for papers by Nicola Normanno Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Frédérique Penault‐Llorca Breakdown of academic impact, for papers by Kazuto Nishio Breakdown of academic impact, for papers by Masakazu Toi
Rankless by CCL
2026